Cargando…
An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the w...
Autores principales: | Estrada, Josue Antonio, Cheng, Chien-Yu, Ku, Shin-Yen, Hu, Hui-Chun, Yeh, Hsiu-Wen, Lin, Yi-Chun, Chen, Cheng-Pin, Cheng, Shu-Hsing, Janssen, Robert, Lin, I-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146038/ https://www.ncbi.nlm.nih.gov/pubmed/35632411 http://dx.doi.org/10.3390/vaccines10050655 |
Ejemplares similares
-
Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
por: Ali, Azhar, et al.
Publicado: (2022) -
Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination
por: Robichaud, Julie, et al.
Publicado: (2021) -
Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
por: Lee, Hyo Jin, et al.
Publicado: (2023) -
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
por: Al Rawahi, Bader, et al.
Publicado: (2021) -
Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine
por: Clayton-Chubb, Daniel, et al.
Publicado: (2021)